Abstract
Background: Adavosertib, a selective Wee1 tyrosine kinase inhibitor, has recently demonstrated potent anticancer activity across multiple tumor types. This study aimed to evaluate the in vitro anticancer effects of Adavosertib on the human cholangiocarcinoma cell line TFK1.
Materials and Methods: The human cholangiocarcinoma TFK1 cell line was treated with varying concentrations of Adavosertib. The study used WST-1 assay, Crystal Violet assay and cell migration assay to evaluate the effect of Adavosertib on TFK1 cells. Results: Adavosertib inhibited TFK1 cell proliferation in a dose-dependent manner, with an IC₅₀ of 0.859 µM. After two weeks of treatment, Adavosertib significantly reduced the area of TFK1 cell clusters in a concentration-dependent fashion. At concentrations ranging from 0.125 to 0.500 µM, Adavosertib did not impair the migratory ability of TFK1 cells.
Conclusion: Adavosertib effectively suppressesed proliferation of the human cholangiocarcinoma TFK1 cell line in vitro.
| Published | 2025-12-25 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 15 No. 7 (2025) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2025.7.16 | |
| Keywords | Ung thư đường mật, Adavosertib, Chất ức chế Wee1, TFK1 Cholangiocarcinoma, Adavosertib, Wee1 inhibitor, TFK1 |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Hue Journal of Medicine and Pharmacy
Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168-79.
Saha SK, Zhu AX, Fuchs CS, Brooks GA. FortyYear Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist. 2016;21(5):594-9.
Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019;39 Suppl 1:7-18.
Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934-40.
DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirtyone-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755-62.
Geenen JJJ, Schellens JHM. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer. Clin Cancer Res. 2017;23(16):4540-4.
Matheson CJ, Backos DS, Reigan P. Targeting WEE1 Kinase in Cancer. Trends Pharmacol Sci. 2016;37(10):872-81.
Bi S, Wei Q, Zhao Z, Chen L, Wang C, Xie S. Wee1 Inhibitor AZD1775 Effectively Inhibits the Malignant Phenotypes of Esophageal Squamous Cell Carcinoma In Vitro and In Vivo. Front Pharmacol. 2019;10:864.
Yang L, Shen C, Pettit CJ, Li T, Hu AJ, Miller ED, et al. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy. Clin Cancer Res. 2020;26(14):3740-50.
Lee YY, Cho YJ, Shin SW, Choi C, Ryu JY, Jeon HK, et al. Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer. Sci Rep. 2019;9(1):15394.